Introduction
Correct haemostasis functioning (the balance between thrombosis and fibrinolysis) is an essential physiological process. Increased thrombosis and/or impaired fibrinolysis leads to life-threatening conditions such as ischaemic stroke, myocardial infarction and pulmonary embolism. Conversely, failure of thrombosis (perhaps to due over-anticoagulation) and/or excessive fibrinolysis leads to life threatening haemorrhage, such as of the gastro-intestinal tract and in causing haemorrhagic stroke (1, 2) . The need for information regarding the potential occurrence of these events, their treatment with anti-coagulants, in stable thrombotic disease such as coronary artery disease and atrial fibrillation, in critical conditions such as disseminated intravascular coagulopathy and trauma, and in investigating cardiovascular pharmacology, such as the effects of anti-coagulants, call for reliable laboratory tests of haemostasis (3, 4) .
The thrombelastograph (TEG) is an established laboratory tool for the investigation and management of haemostasis, simultaneous delivering numerous indices on various aspects of clot formation and fibrinolysis, a selection of which are shown in table 1 (5, 6) . Despite its flexibility in being able to assess haemostasis in trauma, haemorrhage and the effects of anticoagulation and fibrinolysis (7) (8) (9) , it has several disadvantages. These include the requirement of whole blood to be assessed in real time, a maximum of two samples to be assessed per analyser at the same time, relatively high coefficients of variation, poorly standardized methodologies, quality control/assurance issues, and limitations on the stability of whole blood samples (10) (11) (12) . These issues also mean it is a poor choice of assay in clinical research and drug development. Although used most commonly with whole blood, some of these problems may be addressed by using plasma, and the use of frozen plasma allows non-urgent assessments to be batched, possibly to be processed out of hours.
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The insoluble nature of the fibrin clot, and so the interruption of beam of light whilst it forms, it an established feature of the laboratory assessment of thrombogenesis (13) (14) (15) (16) . Based on these principles, we set out to develop and validate a micro-method for a high-throughput assay that can assess thrombogenesis and fibrinolysis in citrated plasma, and that may be useful in clinical practice and research. We determined that the most convenient and efficient platform for this would be a standard 96-well microtitre plate, and we compared our method with parallel data obtained from an established haemostasis device, i.e. the TEG.
Subjects, Materials and Methods

Subjects
Following local research ethics committee approval and written informed consent, whole blood was obtained from 19 healthy (i.e. not taking prescription medications) volunteers (mean age 35, standard deviation 8, range 26 -52 years old, 12 males) into citrated vacutainers. A portion of whole blood was processed on the TEG. Plasma was obtained following centrifugation of the latter for 20 minutes at 3000 rpm: an aliquot of the fresh plasma was processed promptly while some plasma was frozen immediately and stored at - 
General principles of the assays
When plasma is exposed to thrombin, the polymerisation of fibrin can be monitored by measuring the amount of light passing through the solution. As fibrinogen is converted to protofibril monomers and fibrin, this solution will become more turbid and thus cause more
scattering and absorption of light (16) . With subsequent addition of exogenous tissue plasminogen activator (tPA), the solution becomes less turbid due to dissolution of fibrin threads by plasmin, so that light passage is restored. We adopted and amended this process, developing a technique for concurrently assessing both thrombogenesis and fibrinolysis, as these share common features.
The plate assay for thrombogenesis
The method for the thrombogenesis assay calls for 25 µL of plasma to be added to the well of a standard ELISA-quality 96-well microtitre plate (R&D Systems Europe Ltd, Abingdon. The plate is immediately loaded into a Tecan Sunrise plate reader as for the thrombogenesis assay, and data collected for 30 minutes. Again, the raw data of the OD at each time point can be printed out as an excel file and as a graphic. A typical graphical print-out is presented in Figure 2 , and shows change in OD over time as the fibrin clot is initially formed and then lysed. The data is post-processed to plot into line charts, and from these the rate of clot dissolution (RCD), being the slope of the right hand portion of the graph, and the time for 50% clot lysis (T50) can be determined (as demonstrated in Figure 2 ).
As the parameters and settings for the plate reader are identical for each assay, they can be performed in parallel on the same plate. However, should it be necessary, each assay can be TEG and maximum clot density (MCD) in thrombogenesis assay represent the final formation of the mature clot. As the TEG reports autolysis, whereas in our plate assay, lysis is by exogenously added tPA, we did not feel the two assays to be comparable. Indeed, it can be noted that autothrombolysis is both slower and less marked (figure 3) compared to fibrinolysis by added tPA in the plate assay (figure 2).
Validation
The intra-and inter-assay coefficients (CV) of the plate assay indices were determined by 
Results
Reproducibility
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The intra-assay and inter-assay CVs for the microplate assays are shown in Table 2 , those of the TEG assay indices in Table 3 . Note that there is no data for the LY30 in the TEG assay data. This is because there was no change in the MA at 30 minutes -i.e. no clot lysis had occurred. We speculate therefore that the freezing and thawing of plasma and the addition of the kaolin/calcium chloride essentially destroys autolytic potential. This may possibly be of the plasma's own tPA, because exogenous tPA was able to lyse the clot in the plate assay.
The median (interquartile range, IQR) CV of the 20 indices from the plate assays ( 
Time between venepuncture and processing
The effect of time on the haemostasis indices is shown in Table 4 for the plate assays and Table 5 for the TEG. The plate assay (Table 4) 
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statistically not diferent 12 hours after preparation, there is a clear change from the six hour to the 12 hour samples. We therefore recommend that samples are processed not longer than six hours after preparation.
Parallel TEG data are shown in Table 5 . Broadly speaking, most samples were stable to 24 hours after preparation. The only index that did show a statistical change was the α-angle, assessing the rate of thrombogenesis, which showed that samples clotted more rapidly at 3 and 24 hours after preparation (both p=0.019). As there is no clear physiological mechanism for these variations, we suggest this may simply reflect assay variability (as demonstrated by the high CVs). There is also a trend towards reduction of R-time, but this change is not statistically significant. 
Economic Evaluation
Excluding the cost of purchase or rental of microplate reader or TEG analyser, there is a significant difference in cost of processing samples. Taking catalogue costs for reagents, the cost of processing a sample on the TEG is £14.33 versus £1.65 by plate assays when samples are processed in triplicates. By processing huge numbers of samples, the cost per sample in plate assays will be expected to fall, due to the initial start-up cost of bulk purchase of laboratory chemicals. For 5000 samples, cost of each sample processed will remain at £15 for TEG but fall to under £0.35 for plate assays. However, the plate assay demands much more
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Discussion
The ability to reliably, rapidly and accurately assess haemostasis is an important part of clinical and laboratory medicine and vascular pharmacology, and within this process, the value of determining thrombotic and fibrinolytic potential is becoming recognised (1-4) . One of the most useful tools in this respect is the TEG, although it has several disadvantages (5-12), some of which have led to the development of alternative methods (13) (14) (15) (16) .
The TEG technology is well-established, and has been in use for decades in clinical setting as a "point-of-care" assessment of coagulation potential in critically ill patients and those who have experienced poly-trauma (17, 18) . Nevertheless, in some circumstances, such as haemophilia and in point of care testing, other methods may be better (19, 20) . Indeed, as shown in this paper, the large CVs in the TEG data have a significant impact on the reproducibility of the results. The large CVs, the fairly long processing time, the limited number of channels per analyser and the cost of the assay are a significant drawback of this method. Hence, in comparing the TEG with our thrombogenesis and fibrinolysis plate assays, the latter have lower CVs, faster running speed and cheaper processing cost, so may potentially be a viable alternative to TEG. The plate assays also allow for batch analysis after prior freezing and still provides for reliable results, but a drawback is the need for manual post-processing to obtain the results.
The two systems do not draw exact comparison. Correlation analysis shows that despite the similarities in certain components of both the TEG and plate assays, such as the relationship
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between maximum amplitude (reflecting the tensile strength of developed clot) and maximum clot density (reflecting the thickness of fibrin clot monomers), both methods are not identical, but may be complementary. The TEG measures the haemostasis of whole blood or plasma (to which is added kaolin) through coagulation kinetics, clot tensile strength and subsequent clot retraction and autolysis. These contrast with the thrombogenesis and fibrinolysis plate assay, which provides data affecting coagulation, such as direct measurement of the rate of fibrin clot formation and polymerisation, together with the fibrin clot monomer thickness, and a further test of fibrin clot lysis assisted by added tPA. It remains to be seen whether or not the plate assays offer a more useful assessment of haemostasis than the TEG in a clinical setting. A limitation of our data is that it is based on samples from healthy subjects much younger than those whose haemostasis is likely to be assessed in a clinical setting.
Conclusion
We present a microplate assay for measuring thrombogenesis and fibrinolysis which has significantly better intra-assay and inter-assay CVs than TEG technology. Furthermore, results are stable for up to 6 hours from venepuncture, and the plate assay is cheaper and faster to operate. Table 7 summarises the advantages and disadvantages of the two methods.
We believe our new method has potential in both clinical and research (drug development) settings where the quantifiable effects of anticoagulants are important considerations. 
R-time
The time from when the sample is put on the TEG until the first sign of clot formation (amplitude of 2 mm) is reached.
K-time
The time from the R or beginning of clot formation to a fixed level of clot firmness (amplitude of 20 mm) is reached.
Angle (α)
The rate of clot growth.
MA (Maximum Amplitude)
Maximum strength or stiffness (maximum shear modulus) of the developed clot. MA measures the strength or elasticity of the clot in mm.
LY30
Measures percent lysis at 30 minutes after MA is reached. Data are %. CV = coefficient of variation, OD = optical density IQR = inter-quartile range Date are mean (standard deviation). LT = lag time, MCD = maximum clot density, RCD = rate of clot dissolution, RCF = rate of clot formation, T50 = time for 50% of the clot to be lysed, OD = optical density. *p<0.001 compared to baseline. The plot shows changes in optical density as the fibrin clot forms. Triplicate plots are shown. T100% is the time to maximum absorbance, T0% is the return of the optical denity to nearbaseline. T50% is (T100% -T0%)/2. The slope is the sharpest fall in optical density over time under the effect of exogenous tPA, effectively the reverse of the rate of clot formation in Figure 1 . 1  7  13  19  25  31  37  43  49  55  61  67  73  79  85  91  97  103  109  115  121  127  133  139  145  151  157  163  169  175 
